KaloBios Pharma (KBIO) Continues Run-Up on Epic Short Squeeze

KaloBios Pharma (KBIO) CEO to Appear on Bloomberg TV

November 24, 2015 8:53 AM EST

KaloBios Pharma's (NASDAQ: KBIO) CEO Martin Shkreli will be on Bloomberg TV at around noon, he said via twitter.

I'll be on Bloomberg TV around noon, talking about my turnaround plan for $KBIO. Tune in!

Martin Shkreli (@MartinShkreli) November 24, 2015

... More

KaloBios Pharma (KBIO) Receives NASDAQ Delisting Notice

November 23, 2015 5:46 PM EST

The NASDAQ Stock Market notified KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), by letter dated November 17, 2015, that the Company is not currently in compliance with Nasdaqs continued listing requirement set forth in Rule 5250(c)(1) of the Nasdaq Listing Rules (the Rules), due to its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 (the 2015 Third Quarter 10-Q) with the Securities and Exchange Commission (the SEC).

Under the Rules, the Company has 60 calendar days from November 17, 2015 to submit a plan to Nasdaq to regain compliance with the Rules. The Company intends to file... More

KaloBios Pharma (KBIO) Names Martin Shkreli as CEO

November 20, 2015 6:16 AM EST

KaloBios Pharma (NASDAQ: KBIO) announced that an investor group led by Martin Shkreli, the Founder and Chief Executive Officer of Turing Pharmaceuticals AG, has acquired 70% of its outstanding shares. KaloBios also announced the appointment of Martin Shkreli to the position of Chief Executive Officer and his election as Chairman of the Board. In his new role, Mr. Shkreli will work with the company's senior management team to ensure the Company's continued operations. KaloBios further announced that David... More

Shock of Epic Short Squeeze in KaloBios Pharma (KBIO) Reverberates Across Wall Street

November 19, 2015 1:36 PM EST

The stock being talked about the most on trading desks today is KaloBios Pharma (NASDAQ: KBIO). After closing at around $2 per share, shares surged to as high as $21.05 (+953%) following a disclosure after the close from Turing Pharmaceuticals' Martin Shkreli, a man demonized for jacking up drug prices, that he accumulated 1.2 million shares.

$2... $4... $6... $10... $12... shares keep climbing as short sellers were left stunned.

You see, just... More

KaloBios Pharma (KBIO) In Discussions with Shkreli Group About Continuing Operations

November 19, 2015 6:22 AM EST

KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) announced that it has been informed that an investor group comprised of Martin Shkreli and associates together have acquired more than 50% of the outstanding shares of KaloBios, and that the company is in discussions with Mr. Shkreli regarding... More